Asst. Prof. Ebru BİLGET GÜVEN
Contact:
Office: D304
Phone: +90 212 533 65 32 / 1357
e-mail: ebru.bguven@khas.edu.tr, bilget@bilkent.edu.tr
Education:
 |
Undergrad: | Boğaziçi University – Chemistry (1997) |
 |
Master: | Çukurova University – Medicinal Biochemistry (1999) Supervisor: Prof. Kıymet Aksoy |
 |
PhD: | Bilkent University – Molecular Biology and Genetics (2012) Supervisor: Prof. Rengül Çetin Atalay |
Academic Experience:
 |
Postdoc | Ankara University – Faculty of Pharmacy Supervisor: Prof. Meral Tunçbilek |
|
Instructor | Bilkent University – Molecular Biology and Genetics (2013-2015) |
 |
Asst. Prof. |
Kadir Has University – Dept of Bioinformatics and Genetics (2016 – now) |
Awards:
Sanovel Pharmaceuticals Inc., Drug Research Award (1st place) received for the article published in J Med Chem (PMID: 2240977) (2012)
Full Scholarship for Ph.D. studies from TÜBİTAK (The Scientific and Technological Research Council ofTurkey) tenable at Bilkent University (2006-2012)
Courses Given:
MBG 105 Principles of Biology (Bilkent)
MBG 110 Introduction to Modern Biology (Bilkent)
MBG 312 Biochemistry II (Bilkent)
CH101 Chemistry
CH103 Chemistry I
CH104 Chemistry II
BIO105 Introduction to Modern Biology
BIO305 Biochemistry I
BIO306 Biochemistry II
Membership:
American Chemical Society – associate member
Boğaziçi University Alumni (BUMED)
Research:
Hepatocellular carcinoma
Cell culture
In cellulo drug screen
Past and Current Projects:
 |
DPT (State Planning Organization of Turkey) Cancer Drug Technologies, KANILTEK Project. (Assoc.Prof. Rengul Cetin-Atalay’s Lab, coordinator: Prof. Mehmet Öztürk) ($1 500 000). Researcher. |
 |
TÜBİTAK – 112S030. The assessment of the in vivo antitumor effects of a novel small molecule, Cl-ATTM. (Rengul Cetin-Atalay’s Lab) Researcher. |
| |
TÜBİTAK – 112S182. Synthesis of the New Nucleoside and Nucleobase Analogues Cytotoxic to Liver Cancer Cells and Determination of their Effects on Protein Kinases. (Prof. Meral Tuncbilek’s Lab). Researcher. |
Recent Publications:
Tuncbilek M, Kucukdumlu A, Bilget Guven E, Altiparmak D, Cetin-Atalay R. “Synthesis of novel 6-substituted amino-9-(B-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.” Bioorg Med Chem Lett. 2018 Jan 2. PubMed PMID: 29326016. (2018)
Kucukdumlu A, Tuncbilek M, Bilget Guven E, Cetin-Atalay R. “Synthesis of Some Substituted 6-Phenyl Purine Analogues and Their Biological Evaluation as Cytotoxic Agents.” Acta Chim Slov. 2017 Sep; 64(3):621-632. PubMed PMID: 28862295. (2017)
Durmaz I, Bilget Guven E, Ersahin T, Ozturk M, Calis I, Cetin-Atalay R. “Liver cancer cells are sensitive to Lanatoside C induced cell death independent of their PTEN status.” Phytomedicine. 2016 Jan 15; 23(1):42-51. PubMed PMID: 26902406. (2016)
Demir Z, Bilget Guven E, Ozbey S, Kazak C, Atalay RC, Tuncbilek M. “Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.” Eur J Med Chem. 2015 Jan 7;89:701- 20. (contributed equally) PubMed PMID: 25462277. (2015)
Tuncbilek M, Bilget Guven E, Onder T, Cetin Atalay R. “Synthesis of novel 6-(4-substituted piperazine-1- yl)-9-(β-D-ribofuranosyl) purine derivatives, which lead to senescence-induced cell death in liver cancer cells.” J Med Chem. 2012 Apr 12;55(7): 3058-65. PubMed PMID: 22409771. (2012)
Gezici O, Durmaz I, Bilget Guven E, Unal O, Ozgun A, Cetin-Atalay R, and Tuncel D. “Dual functionality of conjugated polymer nanoparticles as an anticancer drug carrier and a fluorescent probe for cell imaging.” RSC Adv., 2013. (2013)